GSK PLC's (LSE:GSK, NYSE:GSK) latest quarter looked strong enough on pape, but the share price barely moved.
The drugmaker has spent much of the past decade trapped between £15 and £18, and Deutsche Bank thinks that pattern is unlikely to change soon.
Third-quarter results brought a brief burst of enthusiasm, helped by solid growth and a renewed push behind the company’s long-term sales goal of £40 billion by 2031.
That target, first set by outgoing chief executive Emma Walmsley, was reaffirmed by her successor during the results call, soothing any fears of a strategic reset.
Management also stuck to its forecast of operating margins above 31% in 2026, with room for further improvement beyond that.
Even so, Deutsche argues the stock’s valuation tells a story of cautious realism. Earnings per share have been rising steadily, but the market’s willingness to pay up for them has waned.
The bank points out that GSK’s price-to-earnings multiple has compressed from the mid-teens to the high single digits over time, a reflection of investors’ wariness about patent expiries, notably the looming loss of exclusivity for its HIV treatment dolutegravir around 2028–29.
With shares closing at 1,777.5p (up 1%), GSK now trades above Deutsche’s new target range of 1,450p to 1,600p.
The rating stays at “hold”, and the tone is one of tempered respect: a business executing well, but hemmed in by its own maturity. For now, steady rather than spectacular looks to be the GSK way.